Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus OXYLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus OXYLONE.
ARAZLO vs OXYLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating transcription of anti-inflammatory proteins and suppressing immune response.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply topically to affected area twice daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 1.5-2.5 hours. Clinical context: Short half-life necessitates multiple daily dosing for sustained anti-inflammatory effect; accumulation minimal with repeated dosing.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: 70-90% (as metabolites, mainly 6β-hydroxycortisol and other conjugates); Biliary/fecal: <10%; Unchanged drug: <5% in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid